- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03721692
Remote Ischemic Conditioning in Acute Ischemic Cerebral Vascular Disease Patients With Coexistence of Cerebral and Coronary Atherosclerosis(RIC-CCCA)
October 30, 2018 updated by: Ji Xunming,MD,PhD, Capital Medical University
Remote ischemic conditioning(RIC) is a protective systemic strategy by organs brief and sublethal ischemia to confer protection from subsequent severe ischemia in distant organs, especially for heart and brain.
This study will discuss whether RIC can play a part in preventing the patients with coexistence of cerebral and coronary atherosclerosis from the recurrence of cerebral vascular disease(CVD) or coronary artery disease(CAD).
This study selects patients who suffered an ischemic stroke within 14 days prior to enrollment.
All patients complete cerebral and coronary artery assessment.
And then the the investigators select the patients who both have at least one cerebral vascular and at least one coronary artery stenosis over 50%, or the patients who both have at least one cerebral vascular stenosis over 50% and myocardial ischemic events history.
These patients will randomly divide into two groups, RIC group and non-RIC group.
Non-RIC group will only accept cardio-cerebrovascular disease secondary prevention treatment.
RIC group will use not only cardio-cerebrovascular disease secondary prevention treatment, but also RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
For the first month, the the investigators will call RIC group patients every week for insuring compliance and adverse effect.
All patients will follow up endpoint events, cardio-cerebrovascular disease secondary prevention treatment, and the adverse effect every three months, up to one year.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
392
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Xuanwu Hospital, Capital Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who suffered an ischemic stroke within 14 days prior to enrollment
- With a baseline NIHSS score 0-15, mRS score 2-4
- With at least one cerebral and carotid artery stenosis over 50%
- With at least one coronary artery stenosis over 50% or previous myocardial ischemic events history(tertiary hospital doctors judge angina, myocardial infarction, and coronary revascularization treatment)
- Age from 18 to 80
- Informed consent obtained
Exclusion Criteria:
- Thrombolytic therapy within 24 h prior to enrollment
- Progressive neurological signs within 24 h prior to enrollment
- Arterial stenosis due to unequivocal cardiac source of embolism, arterial dissection, vasculitic disease, cerebral venous thrombosis, Moyamoya disease
- Arterial stenosis due to benign angiopathy of central nervous system, post-partum angiopathy, suspected vasospastic process, suspected recanalized embolus, neurosyphilis, any other intracranial infection
- Rheumatic mitral disease with or without aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, patent foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis
- Uncontrolled severe hypertension, defined by sitting systolic blood pressure(SBP) > 180 mm Hg and/or sitting diastolic blood pressure(DBP) > 110 mm Hg after medication
- Contraindication for remote ischemic conditioning, including severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs
- Subclavian arterial stenosis 50% or subclavian steal syndrome
- Severe hemostatic disorder or severe coagulation dysfunction, platelets < 100 ×10^9/L
- Aspartate aminotransferase(AST) and/or Alanine aminotransferanse(ALT) > 3× the upper limit of the reference range; creatinine clearance < 0.6 mL/s and/or serum creatinine > 265 mmol/L (>3.0 mg/dL)
- Unwilling to comply with the treatment or follow-up assessments
- Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, or epidural) within 90 days prior to enrollment
- Intracranial neoplasm, cerebral aneurysm, or arteriovenous malformation
- Retinal hemorrhage or visceral bleeding within 30 days prior to enrollment
- Major surgery, including cardiac and open femoral, aortic, or carotid surgery, within 30 days prior to enrollment or intent to undergo within 12 months after enrollment
- Life expectancy < 3 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: RIC group
The patients will accept cardio-cerebrovascular disease secondary prevention treatment and use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
|
The patients will use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
|
NO_INTERVENTION: non-RIC group
The patients will only accept cardio-cerebrovascular disease secondary prevention treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complex ischemic cardio-cerebrovascular events cumulative incidence
Time Frame: 1 year
|
include non-fatal acute ischemic cerebral vascular disease, non-fatal acute coronary syndrome, cardio-cerebrovascular events lead to death, elective cardio-cerebralvascular revascularization, myocardial and cerebral ischemia lead to hospitalize
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Outcome Events Occur
Time Frame: 1 year
|
The first time of the primary outcome events occur
|
1 year
|
Rate of all-cause death
Time Frame: 1 year
|
One year all-cause death rate
|
1 year
|
Score of Modified Rankin Scale(mRS)
Time Frame: 3 months
|
The Modified Rankin Scale Score (mRS) is the most comprehensive and most widely used primary outcome measurement to assess the neurological functional disability in contemporary acute stroke trials.
The mRS is an ordinal, graded interval scale that assigns patients among 7 global disability levels, which ranges from 0 (no symptom) to 5 (severe disability) and 6 (death).
We will use mRS to evaluate the degree of disability or dependence during daily activities.
The mRS will be assessed by certified study investigator at 3 months.
The distribution of mRS will be compared between groups
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 17, 2018
Primary Completion (ANTICIPATED)
July 1, 2024
Study Completion (ANTICIPATED)
December 1, 2024
Study Registration Dates
First Submitted
October 22, 2018
First Submitted That Met QC Criteria
October 25, 2018
First Posted (ACTUAL)
October 26, 2018
Study Record Updates
Last Update Posted (ACTUAL)
October 31, 2018
Last Update Submitted That Met QC Criteria
October 30, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIC-CCCA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Cerebral Vascular Disease
-
University of CalgaryNot yet recruitingIschemic Stroke | Cerebral Small Vessel Diseases | Stroke, Acute | Vascular Cognitive Impairment | Cerebral Small Vessel Ischemic Disease
-
Euphrates Vascular, Inc.RecruitingAcute Ischemic Stroke AIS | Cerebral Arterial DiseaseUnited States
-
Germans Trias i Pujol HospitalFundació Institut Germans Trias i PujolCompletedIschemic Stroke, AcuteSpain
-
University of AlbertaRecruitingSmall Vessel Cerebrovascular Disease | Stroke, Acute IschemicCanada
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
Capital Medical UniversityCompletedAcute Coronary Syndrome | Elderly Patients | Acute Ischemic StrokeChina
-
Pharmazz, Inc.Not yet recruitingAcute Ischemic Stroke | Cerebral Stroke
-
Beijing Tiantan HospitalRecruiting
-
Beijing Tiantan HospitalLinyi People's HospitalActive, not recruitingThrombolysis | Ischemic Stroke, Acute | Endovascular TreatmentChina
-
Can Tho Stroke International Services HospitalRecruitingAcute Stroke | Ischemic Stroke, AcuteVietnam
Clinical Trials on RIC
-
Affiliated Hospital to Academy of Military Medical...Xuanwu Hospital, BeijingUnknown
-
Xuanwu Hospital, BeijingNot yet recruitingTakayasu Arteritis | Cerebral Ischemia
-
Ji Xunming,MD,PhDNot yet recruitingResistant Hypertension
-
Yi YangNot yet recruitingIntracranial HemorrhagesChina
-
Ji Xunming,MD,PhDNot yet recruitingAcute Ischemic StrokeChina
-
Capital Medical UniversityRecruitingAcute Stroke | Intracerebral HemorrhageChina
-
Capital Medical UniversityShengli Oilfield Central HospitalNot yet recruiting
-
Capital Medical UniversityUnknownMoyamoya Disease | Pediatric
-
Augusta UniversityGeorgia Rehabilitation InstituteRecruitingCognition Disorder | Age-related Cerebral White Matter ChangesUnited States
-
Clinical Hospital Center RijekaNot yet recruitingMyocardial Ischemic-reperfusion Injury